Frequent detection of human cytomegalovirus in neuroblastoma: A novel therapeutic target?

International Journal of Cancer

Volumn 133, Issue 10, 2013, Pages 2351-2361

  Wolmer Solberg, Nina ^a   Baryawno, Ninib ^b   Rahbar, Afsar ^a   Fuchs, Dieter ^a   Odeberg, Jenny ^a   Taher, Chato ^a   Wilhelmi, Vanessa ^a   Milosevic, Jelena ^b   Mohammad, Abdul Aleem ^a   Martinsson, Tommy ^c   Sveinbjörnsson, Baldur ^b,d   Johnsen, John Inge ^b   Kogner, Per ^b   Söderberg Nauclér, Cecilia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

human cytomegalovirus; neuroblastoma; valganciclovir

Indexed keywords

CD133 ANTIGEN; CYMVENE; GANCICLOVIR; HERMES ANTIGEN; IMMEDIATE EARLY PROTEIN; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SURGERY; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALIGNANT TRANSFORMATION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ENGRAFTMENT; TUMOR ESCAPE; VIRUS DETECTION; VIRUS VIRULENCE;

HUMAN CYTOMEGALOVIRUS; NEUROBLASTOMA; VALGANCICLOVIR;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD44; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG DELIVERY SYSTEMS; FEMALE; GANCICLOVIR; GLYCOPROTEINS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICE; MICE, NUDE; NEUROBLASTOMA; PEPTIDES; PREVALENCE; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883783563     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28265     Document Type: Article

References (50)

1. Brodeur GM,. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
2. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-5.
3. Nigro G, Schiavetti A, Booth JC, et al. Cytomegalovirus-associated stage 4S neuroblastoma relapsed stage 4. Med Pediatr Oncol 1995; 24: 200-3.
4. Wertheim P, Voute PA,. Neuroblastoma, Wilms' tumor, and cytomegalovirus. J Natl Cancer Inst 1976; 57: 701-3.
5. Scholz M, Blaheta RA, Wittig B, et al. Cytomegalovirus-infected neuroblastoma cells exhibit augmented invasiveness mediated by beta1alpha5 integrin (VLA-5). Tissue Antigens 2000; 55: 412-21.
6. Cinatl J, Jr, Vogel JU, Cinatl J, et al. Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int J Cancer 1996; 65: 90-6.
7. Baryawno N, Rahbar A, Wolmer-Solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest 2011; 121: 4043-55.
8. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002; 62: 3347-50.
9. Harkins L, Volk AL, Samanta M, et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002; 360: 1557-63.
10. Harkins LE, Matlaf LA, Soroceanu L, et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae 2010; 1: 8.
11. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-oncology 2008; 10: 10-18.
12. Samanta M, Harkins L, Klemm K, et al. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 2003; 170: 998-1002.
13. Price RL, Bingmer K, Harkins L, et al. Cytomegalovirus infection leads to pleomorphic rhabdomyosarcomas in Trp53+/- mice. Cancer Res 2012; 72: 5669-74.
14. Rahbar A, Stragliotto G, Orrego A, et al. Low levels of human cytomegalovirus infection in glioblastoma multiforme associates with patient survival-a case-control study. Herpesviridae 2012; 3: 3.
15. Rahbar A, Orrego A, Peredo I, et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol 2013; 57: 36-42.
16. Soroceanu L, Cobbs CS,. Is HCMV a tumor promoter? Virus Res 2011; 157: 193-203.
17. Soderberg-Naucler C,. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med 2006; 259: 219-46.
18. Baryawno N, Sveinbjornsson B, Eksborg S, et al. Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol 2008; 10: 661-74.
19. Nigro G, Adler SP,. Cytomegalovirus infections during pregnancy. Curr Opin Obstet Gynecol 2011; 23: 123-8.
20. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993; 11: 1466-77.
21. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27: 289-97.
22. Shen Y, Zhu H, Shenk T,. Human cytomagalovirus IE1 and IE2 proteins are mutagenic and mediate "hit-and-run" oncogenic transformation in cooperation with the adenovirus E1A proteins. Proc Natl Acad Sci USA 1997; 94: 3341-5.
23. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994; 265: 391-4.
24. Cobbs CS, Soroceanu L, Denham S, et al. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res 2008; 68: 724-30.
25. Castillo JP, Frame FM, Rogoff HA, et al. Human cytomegalovirus IE1-72 activates ataxia telangiectasia mutated kinase and a p53/p21-mediated growth arrest response. J Virol 2005; 79: 11467-75.
26. Lee K, Jeon K, Kim JM, et al. Downregulation of GFAP, TSP-1, and p53 in human glioblastoma cell line, U373MG, by IE1 protein from human cytomegalovirus. Glia 2005; 51: 1-12.
27. Hume AJ, Finkel JS, Kamil JP, et al. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 2008; 320: 797-9.
28. Soderberg-Naucler C,. HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 2008; 41: 218-23.
29. Fortunato EA, Dell'Aquila ML, Spector DH,. Specific chromosome 1 breaks induced by human cytomegalovirus. Proc Natl Acad Sci USA 2000; 97: 853-8.
30. Siew VK, Duh CY, Wang SK,. Human cytomegalovirus UL76 induces chromosome aberrations. J Biomed Sci 2009; 16: 107.
31. Albrecht T, Deng CZ, Abdel-Rahman SZ, et al. Differential mutagen sensitivity of peripheral blood lymphocytes from smokers and nonsmokers: effect of human cytomegalovirus infection. Environ Mol Mutagen 2004; 43: 169-78.
32. Luo MH, Rosenke K, Czornak K, et al. Human cytomegalovirus disrupts both ataxia telangiectasia mutated protein (ATM)- and ATM-Rad3-related kinase-mediated DNA damage responses during lytic infection. J Virol 2007; 81: 1934-50.
33. Martinsson T, Sjoberg RM, Hedborg F, et al. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res 1995; 55: 5681-6.
34. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. New Engl J Med 1996; 334: 225-30.
35. Diskin SJ, Hou C, Glessner JT, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature 2009; 459: 987-91.
36. Caren H, Kryh H, Nethander M, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA 2010; 107: 4323-8.
37. Bongers G, Maussang D, Muniz LR, et al. The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest 2010; 120: 3969-78.
38. Maussang D, Langemeijer E, Fitzsimons CP, et al. The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer Res 2009; 69: 2861-9.
39. Maussang D, Verzijl D, van Walsum M, et al. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 13068-73.
40. Slinger E, Maussang D, Schreiber A, et al. HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal 2010; 3: ra58.
41. Straat K, Liu C, Rahbar A, et al. Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst 2009; 101: 488-97.
42. Opitz OG,. Telomeres, telomerase and malignant transformation. Curr Mol Med 2005; 5: 219-26.
43. Ahlfors K,. IgG antibodies to cytomegalovirus in a normal urban Swedish population. Scand J Infect Dis 1984; 16: 335-7.
44. Forbes BA,. Acquisition of cytomegalovirus infection: an update. Clin Microbiol reviews 1989; 2: 204-16.
45. Odeberg J, Wolmer N, Falci S, et al. Human cytomegalovirus inhibits neuronal differentiation and induces apoptosis in human neural precursor cells. J Virol 2006; 80: 8929-39.
46. Odeberg J, Wolmer N, Falci S, et al. Late human cytomegalovirus (HCMV) proteins inhibit differentiation of human neural precursor cells into astrocytes. J Neurosci Res 2007; 85: 583-93.
47. Han GP, Li L, Kosugi I, et al. Enhancement of susceptibility of adult mouse brain to cytomegalovirus infection by infusion of epidermal growth factor. J Neurosci Res 2007; 85: 2981-90.
48. Sanai N, Alvarez-Buylla A, Berger MS,. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353: 811-22.
49. Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer 2013, doi: 10.1002/ijc.28111.
50. Cinatl J, Jr, Cinatl J, Vogel JU, et al. Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells. Cancer Res 1998; 58: 367-72.